iECURE: Funding, Investors & Team (Aug 2026)
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
iECURE has raised $50.0M across 1 funding round on record, the most recent a Series A of $50.0M announced in Sep 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
iECURE Company Profile and Key Stats
Latest funding round on record: Sep 2021.
iECURE Funding Rounds
iECURE Founders and Leadership Team
Contact details for the iECURE team: 1 of 1 has an email address on file.
Start 14-day free trial →iECURE Funding Compared to Other Biotechnology Startups
iECURE's latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like iECURE in Biotechnology and Philadelphia
Companies Similar to iECURE
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
iECURE Funding FAQs
What does iECURE do?
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
How much funding has iECURE raised?
iECURE has raised $50.0M across 1 round on record. The most recent is a Series A of $50.0M announced in Sep 2021.
When did iECURE last raise funding?
iECURE's most recent funding round on record is a Series A of $50.0M, announced in Sep 2021.
Who is the CEO of iECURE?
Joseph Truitt is listed as CEO at iECURE.
Where is iECURE headquartered?
iECURE is based in Philadelphia, Pennsylvania, United States.
How many employees does iECURE have?
iECURE is in the 1-10 employee band.
How does iECURE's funding compare to other Biotechnology startups?
iECURE's latest round of $50.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's iECURE Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for iECURE is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.